Literature DB >> 16613331

Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis.

Pinak S Acharya1, Alicia Zukas, Vishal Chandan, Anna-Luise A Katzenstein, Ellen Puré.   

Abstract

Fibroblast activation protein (FAPalpha) is a member of the cell surface dipeptidyl peptidase (DPP) family of serine proteases. In its dimer form, FAPalpha exhibits gelatinase, collagenase, and DPP activity in vitro. Reactive fibroblasts in healing wounds and stromal fibroblasts associated with epithelial tumors express FAPalpha. Idiopathic pulmonary fibrosis (IPF) is a disease of the lung characterized by progressive fibrosis with no clear etiology or molecular marker for disease activity. Recently, it has been shown that fibroblast FAPalpha expression is induced in liver cirrhosis, with an expression pattern distinct from alpha-smooth muscle actin (alpha-SMA). In this study, we determine whether FAPalpha expression is selectively induced in areas of ongoing tissue remodeling characterized by fibroblast foci in IPF. Human lung tissue was obtained from patients with IPF, centrilobular emphysema, and normal lung. Immunohistochemical studies were performed using anti-FAPalpha antibody and antibodies against alpha-SMA and CD26 (DPPIV), another member of the DPP family. We found that FAPalpha was not expressed in normal human lung tissue or tissue with evidence of centriacinar emphysema, but was induced in all patients with IPF and With a pattern distinct from that of CD26 found primarily on hyperplastic alveolar epithelium. Specifically, FAPalpha was detected in fibroblast foci and in fibrotic interstitium and not in the interstitium of adjacent architecturally normal lung. Alveolar/airway epithelium and vascular smooth muscle did not express FAPalpha. This is the first report of FAPalpha expression in IPF and our results suggest that FAPalpha is selectively induced in fibrotic foci, but not in normal or emphysematous lung. Future studies will address whether FAPalpha may be used as a marker for disease activity in IPF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613331     DOI: 10.1016/j.humpath.2005.11.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  55 in total

Review 1.  Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease.

Authors:  Paolo Giuffrida; Massimo Pinzani; Gino R Corazza; Antonio Di Sabatino
Journal:  United European Gastroenterol J       Date:  2016-03-21       Impact factor: 4.623

Review 2.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

Review 3.  You Say You Want a Resolution (of Fibrosis).

Authors:  Kamran Atabai; Christopher D Yang; Michael J Podolsky
Journal:  Am J Respir Cell Mol Biol       Date:  2020-10       Impact factor: 6.914

4.  Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions.

Authors:  Yan Huang; Avis E Simms; Anna Mazur; Sophie Wang; Noel R León; Barry Jones; Nazneen Aziz; Thomas Kelly
Journal:  Clin Exp Metastasis       Date:  2011-05-22       Impact factor: 5.150

5.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

6.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.

Authors:  Angélica M Santos; Jason Jung; Nazneen Aziz; Joseph L Kissil; Ellen Puré
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

7.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Authors:  Kyung N Lee; Kenneth W Jackson; Simon Terzyan; Victoria J Christiansen; Patrick A McKee
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

8.  Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Authors:  W Nathaniel Brennen; D Marc Rosen; Hao Wang; John T Isaacs; Samuel R Denmeade
Journal:  J Natl Cancer Inst       Date:  2012-08-21       Impact factor: 13.506

9.  Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.

Authors:  W Nathaniel Brennen; D Marc Rosen; Alcides Chaux; George J Netto; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2014-07-22       Impact factor: 4.104

10.  Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art.

Authors:  Clarice Zc Chen; Michael Raghunath
Journal:  Fibrogenesis Tissue Repair       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.